NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress
(WorldNews Netherlands)

NOXXON PRESENTS LATEST CLINICAL DATA FROM PHASE 1/2 NOX-A12 / KEYTRUDA® COMBINATION TRIAL AT THE ESMO CONGRESS WEBCAST POSTER PRESENTATION TOMORROW, SEPTEMBER 30, AT 09.00 A.M. CEST Berlin, Germany, September 29, 2019, 12.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the latest clinical results from the Phase 1/2 study of NOX-A12in combination with Keytruda® (pembrolizumab) in patients with microsatellite-stable,metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology (ESMO) Congress in...